Rigor Reviewed

Rigor-Reviewed Manuscript

Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).

Name: Αlpha¹ Rigor Record — Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).
Item: Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).
Rating: 94
Author: Αlpha¹

Singh M, Joshi S, Vohra V, Sarin R, Kamble SV, Velayutham B, Mohan A, Singh UB, Kumar R, Pati S, Pattnaik M, Mohapatra PR, Shankar U, Narasimhaiah S, Yadav G, Hissar S, Rodrigues R, Kadam AV, Paramasivam PK, Kambhampati S, Newtonraj A, Palaniappan NA, Reddy SD, Bhuniya S, Mishra BK, Shete A, Hanna LE, Mitra DK, Panda S, Guleria R, Tripathy S, Roy N, D'Souza G, Tripathy SK, Katoch K, Pandey RM, Sah S, Kashyap M, Telasey V, Bakshi M, Wadhwa N, Khan AM, Gangakhedkar RR, Rani R

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 5 high issues for “Efficacy and safety of VPM1002 and Immuvac in preventing tuberculosis: phase 3 randomised clinical trial (PreVenTB trial).”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsOverstated claim−0.5★
ReportingData & code availability partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 3 RCT. The main methodological strengths are its rigorous design, comprehensive ethics documentation, and transparent reporting of outcomes. The most notable weaknesses are the incomplete identification of immunogenicity antibodies, the lack of a version-controlled repository for the analysis code, and a few internal consistency errors (Table 6 percentage) and overstatements (subgroup claim for extrapulmonary TB).

Eight dimensions were evaluated. Dimensions related to animal research, cell lines, etc., were marked not applicable. The reviewers converged on most dimensions; the main divergence was on data code availability (one rated warn, one pass) and on the adequacy of the premise rationale and reporting guideline items. The synthesis adopted the more conservative assessment where evidence was clear.

7 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites TB burden statistics and the failure of BCG revaccination in Brazil and Chingleput India to motivate the trial. The rationale for choosing the two specific vaccines is deferred to the published protocol rather than stated in full, and the limitations of prior work are acknowledged only implicitly (BCG's limited protection). The hypothesis follows directly from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleINADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The premise—that prophylactic vaccines are needed beyond BCG to prevent TB—is well established with cited prior work and a clear rationale.

Evidence

direct quote[Introduction]

“BCG is currently the only available licensed vaccine against TB that protects against extreme forms of TB in young children, but does not offer protection against pulmonary TB in adolescents and adults. However, BCG revaccination did not reveal encouraging results even in school age children in Brazil or in adolescents in Chingleput India.”